Of the many mutations that characterize myeloid malignancies, some (TET2, ASXL1) can initiate a preleukemic clone, whereas others (MPL, JAK2) are phenotypic lesions that trigger the overt malignant disease (Vainchenker et al. 2011). Here, MPL is linked to cancer.